📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Biopharmaceutic Study Reports (TILA-278)

Document ID: CLINPHARM-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E

Biopharmaceutic Study Reports — TILA-278

Biopharmaceutic characterisation of TILA-278 (subcutaneous): absolute/relative bioavailability, dose proportionality, and the comparability of the clinical and to-be-marketed presentations. Subcutaneous absorption with typical IgG bioavailability; target-mediated drug disposition (TMDD) producing non-linear PK at low concentrations; distribution largely confined to plasma and interstitial fluid; elimination by proteolytic catabolism and (in the target-mediated component) receptor-mediated clearance. Classical small-molecule ADME (mass balance, CYP/transporter) is not applicable to an intact IgG. ICH M4E §5.3.1.

1. Scope, Regulatory Framework, and Relationship to the Clinical Pharmacology Program

TILA-278 is a humanized IgG1 bispecific monoclonal antibody (anti-TL1A [TNFSF15] antagonist arm / IL-22 receptor [IL-22RA1/IL-10RB] agonist arm) administered subcutaneously for the treatment of moderate-to-severe ulcerative colitis (UC). It is a biological product to be licensed under a Biologics License Application (21 CFR Part 601); the applicable quality, nonclinical, and clinical-pharmacology frameworks include ICH M4E (CTD organisation), ICH M10 (bioanalytical method validation), ICH Q5A(R2) (viral safety of biotechnology products), ICH Q5C (stability of biotechnology/biological products), ICH Q6B (specifications for biotechnological/biological products), and ICH S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals).

The classical small-molecule biopharmaceutic paradigm — dissolution, gastrointestinal permeability, first-pass metabolism, and absolute/relative bioavailability referenced to an oral or intravascular comparator — does not translate directly to an intact ~146-kDa antibody. The biopharmaceutic behaviour of TILA-278 is instead governed by absorption of the antibody from the subcutaneous (SC) depot via convective and lymphatic uptake, neonatal Fc receptor (FcRn)-dependent recycling that confers a long systemic residence, and target-mediated drug disposition (TMDD) arising from binding to both the soluble/membrane TL1A antagonist target and the cell-surface IL-22R agonist target. Accordingly, this Module 5.3.1 report frames the biopharmaceutic assessment around three questions relevant to a parenterally administered therapeutic antibody: (i) the rate and extent of SC absorption and the estimated absolute bioavailability; (ii) the dose–exposure (dose-proportionality) relationship across the clinical dose range; and (iii) the comparability of the presentation used in the clinical program with the intended commercial presentation. Quantitative characterisation of disposition, the population-PK (popPK) model, and covariate effects are reported in full in CLINPHARM-002 (Human Pharmacokinetic Study Report, Module 5.3.3) and are cross-referenced here where they inform biopharmaceutic conclusions.

Both target epitopes are human-restricted, and cynomolgus monkey is the sole pharmacologically relevant nonclinical species; there is no pharmacologically relevant rodent species. Absolute bioavailability therefore cannot be anchored by interspecies (e.g., rodent SC-versus-IV) scaling and is instead estimated by a model-based approach referenced to the well-characterised disposition of human IgG1, as described in Section 4.

2. Investigational Product and Product Presentations

Drug substance. TILA-278 drug substance is a humanized IgG1 bispecific monoclonal antibody produced by fed-batch culture of a recombinant Chinese hamster ovary (CHO) cell line and purified by Protein A affinity capture followed by orthogonal polishing chromatography and validated viral-clearance steps. The intact IgG1 scaffold retains a functional Fc domain for FcRn-mediated recycling, which underlies the antibody-typical long systemic half-life. Product-quality attributes (identity, purity/impurities, charge and size heterogeneity, glycosylation, and potency for each functional arm) are controlled to specifications established under ICH Q6B; viral safety and stability are supported under ICH Q5A(R2) and ICH Q5C, respectively. These CMC elements are reported in Module 3 and are summarised here only insofar as they establish that the clinical and commercial materials are of comparable quality.

Drug product and presentations. TILA-278 drug product is a sterile, preservative-free aqueous solution for SC injection, supplied as single-dose presentations at the 150 mg and 300 mg strengths corresponding to the Low and High regimens. The formulation is a buffered aqueous vehicle at mildly acidic pH containing a sugar stabiliser and a polysorbate surfactant, a composition consistent with a high-concentration SC antibody product designed to preserve conformational and colloidal stability, limit aggregation, and support an injection volume and viscosity suitable for SC self-administration. The clinical presentations were delivered by prefilled syringe and autoinjector.

Clinical versus to-be-marketed presentation. The pivotal induction study TILA278-201 administered TILA-278 by prefilled syringe/autoinjector at 150 mg (Low) and 300 mg (High). The to-be-marketed presentation is of the same qualitative and quantitative composition and the same strengths. The comparability of the clinical and commercial presentations — including the prefilled-syringe and autoinjector configurations of each strength — is addressed in Section 6.

3. Bioanalytical Methods Supporting the Biopharmaceutic Assessment

Serum TILA-278 concentrations underpinning the biopharmaceutic and dose-proportionality analyses were measured with a validated sandwich enzyme-linked immunosorbent assay (ELISA) selective for the intact bispecific molecule, using a capture reagent directed at the anti-TL1A arm and an anti-idiotype detection reagent directed at the IL-22R arm. The method was validated in accordance with ICH M10 with a lower limit of quantitation (LLOQ) of 0.100 µg/mL, an upper limit of quantitation (ULOQ) of 30.0 µg/mL (higher concentrations by validated dilution), a calibration range of 0.100–30.0 µg/mL, inter-assay accuracy of −6.8% to +7.4% (%bias), and inter-assay precision ≤ 11.2% (%CV), with no significant interference from normal or UC serum. Below-limit-of-quantitation (BLQ) values were handled by the likelihood-based (M3) method in the popPK analysis and, in the descriptive non-compartmental analysis, by setting leading BLQ values to zero and treating embedded/terminal BLQ values as missing.

Immunogenicity was assessed with a tiered strategy — an electrochemiluminescence bridging screening assay, a confirmatory drug-competition assay, titre determination for confirmed-positive samples, and arm-specific neutralising-antibody (NAb) assays — with a screening-assay drug tolerance ≥ 25 µg/mL at the low positive control. Full validation details for the concentration and anti-drug-antibody (ADA) assays are provided in BIOANALYTICAL-001; immunogenicity outcomes and their impact on exposure are summarised in Section 9 and reported in full in IMMUNO-001 and CLINPHARM-002.

4. Absorption and Absolute Bioavailability

Following SC administration, TILA-278 was absorbed slowly into the systemic circulation, consistent with lymphatic-mediated uptake of a large protein from the SC depot. In the intensive PK substudy (62 active-arm subjects), the median time to maximum concentration (Tmax) after the first dose was approximately 6 days (range 3–11 days), and the absorption profile was flat, producing only modest peak-to-trough fluctuation at steady state — a desirable feature for a chronically dosed SC biologic. The population-PK first-order absorption rate constant (ka) was 0.264 day⁻¹, corresponding to an absorption half-life of approximately 2.6 days, with a short absorption lag (~0.15 day).

Because TILA278-201 did not include an intravenous (IV) reference arm, absolute SC bioavailability was not directly estimable within the study. Absolute bioavailability was estimated at approximately 64% using a model-based approach anchored to the well-characterised disposition of intact human IgG1 (FcRn-recycled catabolism). This estimate should be interpreted with the caveat that it derives from a cross-referenced disposition assumption rather than an in-study IV comparison; it is nonetheless within the range expected for a full-length SC-administered monoclonal antibody. Consistent with limited extravascular partitioning of an IgG, the central volume of distribution (Vc ≈ 3.18 L) approximated plasma volume and the steady-state volume (Vss ≈ 5.9 L) was confined to the vascular plus interstitial space, so the flat, prolonged absorption from the SC depot — rather than distribution — is the principal determinant of the systemic concentration-time profile.

5. Dose Proportionality and Dose–Exposure Relationship

First-dose non-compartmental parameters (geometric mean [geometric CV%]) characterised early exposure across the two active regimens:

Parameter	TILA-278 Low (150 mg)	TILA-278 High (300 mg)
Cmax (µg/mL)	10.4 (37%)	21.8 (34%)
Tmax (days), median (range)	6.5 (3–11)	6.0 (3–10)
AUC0–14d (µg·day/mL)	98 (41%)	215 (39%)

Steady state was reached during induction with an accumulation ratio of approximately 1.8–2.2 relative to first dose, consistent with the ~19-day terminal half-life and the loading-then-monthly schedule (SC dosing at Weeks 0, 2, 4, 8, and 12). Steady-state (Week 8–12) exposure parameters (geometric mean [geometric CV%]) were as follows:

Parameter	TILA-278 Low (150 mg)	TILA-278 High (300 mg)	High:Low ratio
Cmax,ss (µg/mL)	18.9 (42%)	47.5 (38%)	2.51
Ctrough,ss (µg/mL)	7.4 (54%)	21.6 (46%)	2.92
Cavg,ss (µg/mL)	13.2	34.3	2.60
AUCtau,ss (µg·day/mL)	370 (48%)	961 (41%)	2.60

For a 2-fold increase in dose (150 → 300 mg), AUCtau,ss increased approximately 2.6-fold and Ctrough,ss approximately 2.9-fold — a greater-than-dose-proportional increase in exposure. This is the expected biopharmaceutic consequence of TMDD rather than of any absorption non-linearity: at the lower regimen a larger fraction of drug is eliminated by the saturable, target-mediated pathway (Michaelis-Menten Vmax 0.58 mg/day, Km 0.29 µg/mL), so proportionally more is cleared; at the higher regimen that pathway is more fully saturated, apparent clearance approaches the linear value (CL ≈ 0.201 L/day), and exposure rises faster than dose. The disproportionality is most pronounced for trough concentrations, which sit lower on the concentration axis where target-mediated elimination contributes most. Inter-individual variability in exposure was moderate (geometric CV% ~40–55%), typical for an SC therapeutic antibody in an inflammatory-bowel-disease population.

The dose–exposure relationship is coherent with the exposure-ordered efficacy observed in TILA278-201 (clinical remission at Week 12: 37.3% [106/284] High, 16.2% [46/283] Low, 0.7% [2/273] placebo; modified Mayo LS-mean change −3.36 / −2.76 / −1.00; endoscopic improvement 48.9% / 27.9% / 6.2%): the greater-than-proportional exposure gain from Low to High is accompanied by a substantial gain in remission, supporting the biopharmaceutic basis of the dose selection.

6. Relative Bioavailability and Presentation/Device Comparability

The comparability of the clinical and to-be-marketed presentations rests on two complementary lines of evidence: matched product quality and equivalent systemic exposure. Product-quality comparability between the clinical and commercial materials — identity, purity, size and charge heterogeneity, glycosylation, and arm-specific potency — is established to ICH Q6B specifications in Module 3. On the biopharmaceutic side, the prefilled-syringe and autoinjector configurations of each strength deliver the same nominal 150 mg and 300 mg SC doses in an equivalent injection volume; a comparative-bioavailability (relative-bioavailability) assessment of the delivered presentations demonstrated geometric mean ratios for Cmax and AUC contained within the conventional 0.80–1.25 equivalence interval, supporting interchangeability of the syringe and autoinjector and comparability of the clinical and to-be-marketed presentations. Because a full-length antibody is absorbed from the SC depot with a flat, lymphatically mediated profile, the delivery device is not expected to materially alter the rate or extent of absorption, and the observed comparability is consistent with that expectation. No adjustment to the dosing regimen is required when transitioning from the clinical to the commercial presentation.

7. Food Effect, Route, and Special Biopharmaceutic Considerations

TILA-278 is administered subcutaneously; there is no oral or enteral administration, no first-pass gastrointestinal or hepatic extraction, and consequently no food-effect assessment is applicable. There is no drug-release or dissolution step to modulate, and concepts such as dose-dumping do not apply to a solution presentation of an antibody. Injection-site selection within the labelled SC sites (e.g., abdomen or thigh) may produce only minor differences in absorption for an antibody of this class and does not warrant site-specific dosing. The route also precludes the small-molecule ADME assessments (mass-balance/excretion, CYP-mediated metabolism, and transporter interactions) that are not applicable to an intact IgG, as noted in the synopsis above.

8. In Vitro–In Vivo Correlation and Dissolution

In vitro–in vivo correlation (IVIVC), dissolution testing, and Biopharmaceutics Classification System (BCS) categorisation are not applicable to a parenterally administered therapeutic protein. TILA-278 is presented as a ready-to-inject solution with no solid-state dissolution or gastrointestinal permeability component; systemic input is defined by SC absorption of the antibody rather than by a formulation-controlled release process. No IVIVC is therefore proposed or required for this modality.

9. Intrinsic and Extrinsic Factors Affecting Bioavailability and Exposure

The factors with the greatest influence on TILA-278 exposure are body weight and baseline serum albumin, with a smaller, well-characterised effect of immunogenicity; these were quantified in the population-PK covariate analysis (CLINPHARM-002, Sections 10–11) and are summarised here for their biopharmaceutic relevance. Body weight acted on clearance and central volume (power exponents 0.75 on CL and 1.0 on Vc, centred at 70 kg), and lower serum albumin was associated with higher clearance (exponent −1.05, centred at 40 g/L), reflecting the shared FcRn/catabolic biology and protein loss associated with active mucosal inflammation, such that albumin behaves as a marker of disease burden as well as of enhanced antibody catabolism. Treatment-emergent ADA (High 9.4% [28/298], Low 11.7% [35/299], placebo background 2.0% [6/300]) increased clearance by approximately 28% (categorical multiplier 1.28) and lowered exposure (AUC −22%, Ctrough,ss~ ~−35%), predominantly among the small subset with persistent, neutralising, higher-titre responses; most responses were low-titre and transient.

Despite these effects, the resulting range of exposures remained within the range associated with near-maximal efficacy at the High regimen, and neither body weight, serum albumin, disease activity, nor ADA status warranted dose adjustment at the doses studied. As a large monoclonal antibody, TILA-278 is not eliminated renally or by hepatic cytochrome-mediated metabolism, so clinically meaningful effects of renal or hepatic impairment on exposure are not expected and no dedicated organ-impairment biopharmaceutic study is proposed for this modality.

10. Summary and Conclusions

• The biopharmaceutic profile of TILA-278 is that of an intact SC-administered humanized IgG1 bispecific antibody: slow, flat absorption from the SC depot (median Tmax 6 days; ka~ 0.264 day⁻¹; absorption half-life ~2.6 days), estimated absolute bioavailability of approximately 64% (model-based, referenced to human IgG1 disposition in the absence of an in-study IV arm), and a systemic profile shaped by absorption and TMDD rather than by distribution or a formulation-release step.
• Systemic exposure increased in a greater-than-dose-proportional manner from the Low (150 mg) to High (300 mg) regimen (AUCtau,ss 2.6-fold and Ctrough,ss~ ~2.9-fold for a 2-fold dose increase), reflecting saturation of target-mediated clearance at higher concentrations; this dose–exposure behaviour is coherent with the exposure-ordered efficacy of the two active regimens.
• The clinical and to-be-marketed presentations are comparable in composition and product quality (ICH Q6B), and the prefilled-syringe and autoinjector configurations of each strength are supported as interchangeable, with comparative-bioavailability geometric mean ratios within the 0.80–1.25 equivalence interval; no regimen change is required on transition to the commercial presentation.
• Assessments predicated on the small-molecule paradigm — food effect, IVIVC/dissolution, BCS classification, and classical ADME (mass balance, CYP/transporter) — are not applicable to an intact IgG and are appropriately not pursued.
• Together with the population-PK, immunogenicity, and exposure-response analyses reported in CLINPHARM-002 and IMMUNO-001, these biopharmaceutic findings support the dose selection, the choice of SC presentation, and the comparability of the clinical and commercial products carried forward for the program.

11. Abbreviations

ADA, anti-drug antibody; ADME, absorption/distribution/metabolism/excretion; AUC0–14d, area under the concentration-time curve from 0 to 14 days; AUCtau,ss, area under the concentration-time curve over the dosing interval at steady state; BCS, Biopharmaceutics Classification System; BLA, Biologics License Application; BLQ, below the limit of quantitation; Cavg,ss, average steady-state concentration; Cmax, maximum concentration; Cmax,ss, steady-state maximum concentration; Ctrough,ss, steady-state trough concentration; CHO, Chinese hamster ovary; CL, linear clearance; CMC, chemistry, manufacturing, and controls; CTD, Common Technical Document; CV, coefficient of variation; ELISA, enzyme-linked immunosorbent assay; FcRn, neonatal Fc receptor; IIV, inter-individual variability; IL-22R, interleukin-22 receptor; IV, intravenous; IVIVC, in vitro–in vivo correlation; ka, absorption rate constant; Km, Michaelis-Menten constant; LLOQ, lower limit of quantitation; NAb, neutralizing antibody; PK, pharmacokinetics; popPK, population pharmacokinetics; SC, subcutaneous; TL1A, TNF-like ligand 1A (TNFSF15); TMDD, target-mediated drug disposition; Tmax, time to maximum concentration; UC, ulcerative colitis; ULOQ, upper limit of quantitation; Vc, central volume of distribution; Vmax, maximum rate of nonlinear elimination; Vss, volume of distribution at steady state.

Values marked represent standard, ICH-conformant clinical-pharmacology parameters consistent with a humanized IgG1 bispecific antibody exhibiting target-mediated disposition, where a specific value stands in for the corresponding measured result.